Abstract
Excessive amyloid-β (Aβ) deposition in the brain is one of the most crucial events in the early pathological stage of Alzheimers disease (AD). Therefore, Aβ deposits have enough potential to become a useful biomarker for not only an early diagnosis of AD, but also for the assessment of the clinical efficacy of anti-Aβ therapies, if they can be measured non-invasively and reliably in living patients. As a potent candidate technique to measure this biomarker, PET amyloid imaging using a radioligand for Aβ deposits has received much attention. A large number of Aβ ligands have been synthesized and evaluated as candidates for amyloid imaging agents. These can be classified into six categories of derivatives: Congo-red, Thioflavine T, stilbene, vinylbenzoxazole, DDNP, and miscellaneous. Many of these derivatives exhibit high binding affinities to Aβ fibrils (below 20 nM) and some of them also show excellent brain pharmacokinetic profiles. The concept of amyloid imaging is currently being tested in human PET studies using optimized amyloid imaging agents. Despite the small number of subjects, these studies have demonstrated sufficiently promising results. This review article provides an overview of recent advances in the development of amyloid imaging agents, and includes: a summary of the fundamental basis and clinical significance of amyloid imaging; lists of binding affinity data for 135 compounds classified into 12 molecular frameworks; a comprehensive discussion of the in vitro and in vivo features of representative Aβ ligands; and a discussion of the current state of clinical evaluation of these amyloid imaging agents (PIB, SB-13, BF-227, and FDDNP).
Keywords: Alzheimer's disease, amyloid imaging, radioligand, PIB, SB-13, BF-227, FDDNP
Current Topics in Medicinal Chemistry
Title: Recent Advances in the Development of Amyloid Imaging Agents
Volume: 7 Issue: 18
Author(s): Shozo Furumoto, Nobuyuki Okamura, Ren Iwata, Kazuhiko Yanai, Hiroyuki Arai and Yukitsuka Kudo
Affiliation:
Keywords: Alzheimer's disease, amyloid imaging, radioligand, PIB, SB-13, BF-227, FDDNP
Abstract: Excessive amyloid-β (Aβ) deposition in the brain is one of the most crucial events in the early pathological stage of Alzheimers disease (AD). Therefore, Aβ deposits have enough potential to become a useful biomarker for not only an early diagnosis of AD, but also for the assessment of the clinical efficacy of anti-Aβ therapies, if they can be measured non-invasively and reliably in living patients. As a potent candidate technique to measure this biomarker, PET amyloid imaging using a radioligand for Aβ deposits has received much attention. A large number of Aβ ligands have been synthesized and evaluated as candidates for amyloid imaging agents. These can be classified into six categories of derivatives: Congo-red, Thioflavine T, stilbene, vinylbenzoxazole, DDNP, and miscellaneous. Many of these derivatives exhibit high binding affinities to Aβ fibrils (below 20 nM) and some of them also show excellent brain pharmacokinetic profiles. The concept of amyloid imaging is currently being tested in human PET studies using optimized amyloid imaging agents. Despite the small number of subjects, these studies have demonstrated sufficiently promising results. This review article provides an overview of recent advances in the development of amyloid imaging agents, and includes: a summary of the fundamental basis and clinical significance of amyloid imaging; lists of binding affinity data for 135 compounds classified into 12 molecular frameworks; a comprehensive discussion of the in vitro and in vivo features of representative Aβ ligands; and a discussion of the current state of clinical evaluation of these amyloid imaging agents (PIB, SB-13, BF-227, and FDDNP).
Export Options
About this article
Cite this article as:
Furumoto Shozo, Okamura Nobuyuki, Iwata Ren, Yanai Kazuhiko, Arai Hiroyuki and Kudo Yukitsuka, Recent Advances in the Development of Amyloid Imaging Agents, Current Topics in Medicinal Chemistry 2007; 7 (18) . https://dx.doi.org/10.2174/156802607782507402
DOI https://dx.doi.org/10.2174/156802607782507402 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pre-attentive Visual Processing in Alzheimer’s Disease: An Event-related Potential Study
Current Alzheimer Research Machine Learning Techniques and Drug Design
Current Medicinal Chemistry Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate
Current Alzheimer Research Editorial[Hot Topic:Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Risk Factors for Suicide – An Alternative View
CNS & Neurological Disorders - Drug Targets Tablet Formulation of a Synthesized Celecoxib Potassium Salt and Development of a Validated Method for Its Analysis
Current Pharmaceutical Design Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents New Approaches to Develop Drug Treatment for Alzheimer’s Disease: Targeting Calcium Dysregulation
Current Alzheimer Research Tetracyclines and Neuromuscular Disorders
Current Neuropharmacology Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Boronate Can Be the Fluorogenic Switch for the Detection of Hydrogen Peroxide
Current Medicinal Chemistry Current Concepts on Prenatal Diagnosis and Management of Fetal Tachyarrythmias
Current Cardiology Reviews Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Recent Developments on Synthesis of Indole Derivatives Through Green Approaches and Their Pharmaceutical Applications
Current Organic Chemistry Different Effect of Vitamin D<sub>2</sub> and Vitamin D<sub>3</sub> on Amyloid-β40 Aggregation In Vitro
Current Alzheimer Research Wnt Signaling Pathway in Schizophrenia
CNS & Neurological Disorders - Drug Targets Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Review and Analysis of Massively Registered Clinical Trials of COVID-19 using the Text Mining Approach
Reviews on Recent Clinical Trials COPD: Optimal Current Treatment Strategies and Promising New Therapeutic Modalities
Current Respiratory Medicine Reviews Imaging Reporters and Multimodal Molecular Bio-Imaging: A Database of Available Probes for Multi-Modality Bio-Imaging of Reporter Gene Expression
Recent Patents on Medical Imaging